Several GOP lawmakers criticized the Food and Drug Administration (FDA) after it established a new environment for abortion drugs on Thursday.
This wave of backlash followed the FDA’s approval of new abortion pills produced by Evita Solutions, a company that aims “to normalize abortion care” and ensure “that care is accessible to everyone.”
“This is shocking,” remarked Republican Senator Josh Hawley from Missouri. He stated that “evidence shows that chemical abortion drugs are dangerous, even fatal for mothers,” adding, “The FDA has just approved another chemical abortion drug, and of course, it is 100% deadly for children.”
Hawley expressed his dissatisfaction, saying, “The FDA had promised to conduct the best safety review of chemical abortion drugs, but instead, they greenlighted the new version for distribution. I have lost confidence in FDA leadership.”
The FDA claims that this drug is a generic form of mifepristone, intended to terminate pregnancies up to 70 days into gestation.
Hawley also mentioned the drugmaker’s position on gender ideology. In a recent post, he noted, “The FDA has just approved the distribution of more abortion medications. I don’t believe there is something like ‘woman.'”
According to Evita Solutions’ website, the company believes that everyone should have access to safe and affordable abortion services, irrespective of various factors like race or income.
Republican Representative Riley Moore from West Virginia urged the Health and Human Services (HHS) Secretary and the FDA Commissioner to “reverse course soon,” stating, “Chemical abortion kills children and harms mothers.” The FDA functions under HHS.
Another Republican, Mark Harris, expressed his dismay on social media, pointing out the contradiction of the FDA announcing a new safety investigation while approving mifepristone.
In September, Health and Human Services Secretary Robert F. Kennedy Jr. indicated an investigation into the risks associated with mifepristone, noting that there would be a review of evidence concerning drug safety and efficacy.
Democratic Senator Patty Murray from Washington emphasized that the data clearly supports mifepristone’s safety and effectiveness.
Former Vice President Mike Pence also weighed in, criticizing the FDA’s approval. He remarked on his earlier opposition to Robert F. Kennedy Jr.’s appointment, suggesting it reflects poorly on the administration’s commitment to the pro-life movement.
Pence stated, “President Trump must quickly reverse this decision,” asserting that RFK should resign to allow for new leadership in HHS that aligns with pro-life values.
Evita Solutions, Senator Hawley, Senator Murray, and Representative Moore did not provide immediate responses to requests for comment.
